Integrin-Mediated TGFβ Activation Modulates the Tumour Microenvironment.

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Transforming growth factor-beta (TGFβ) exhibits context-dependent roles in cancer, acting as a tumor suppressor in early stages and a promoter in established tumors.
• TGFβ signaling is crucial in the tumor microenvironment (TME), influencing processes like epithelial-to-mesenchymal transition (EMT), cancer-associated fibroblast (CAF) formation, and angiogenesis.
• Latent TGFβ requires local activation within the TME to exert its functions, with αv-integrins identified as key activators.

Purpose of the Study:

• To review the multifaceted role of TGFβ in cancer progression and immune evasion.
• To elucidate the function of integrins in activating TGFβ within the TME.
• To explore the therapeutic potential of targeting integrins to enhance anti-cancer immunotherapies.

Main Methods:

• Literature review of studies on TGFβ, integrins, and the tumor microenvironment.
• Analysis of mechanisms by which TGFβ influences cancer and immune surveillance.
• Examination of the role of integrin-mediated TGFβ activation in immune suppression.

Main Results:

• TGFβ suppresses normal tissue and early tumors but promotes established cancers via mechanisms including EMT and angiogenesis.
• TGFβ is a potent inhibitor of T-cell-mediated immune surveillance and contributes to immunotherapy resistance.
• Integrins, particularly αv-integrins, are critical for activating latent TGFβ in the TME.

Conclusions:

• TGFβ's dual role necessitates understanding its activation mechanisms in the TME.
• Integrin-mediated TGFβ activation contributes to an immunosuppressive TME.
• Targeting integrins represents a promising strategy to overcome TGFβ-induced immune suppression and augment cancer immunotherapy efficacy.